IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Appl. No.: 10/696,256

Confirmation No. 7071

Applicant: Neal I. Azrolan, et al.

Filed: 10/29/2003

TC/A.U.: 1614

Examiner: Raymond J. Henley III

Docket No.: AM-100302C1USA

Customer No.: 38199

Title: METHOD OF TREATING CARDIOVASCULAR DISEASE

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit to the Examiner the attached Form PTO/SB/08B document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98.

U.S. Patent Application No. 10/696,256 Second Supplemental Information Disclosure Statement Page 2 of 2

REMARKS

The Examiner is respectfully requested to consider the documents identified in the attached Form PTO/SB/08B during the course of examination of this application.

This Information Disclosure Statement is being filed with a Request for Continued Examination, therefore no fees are believed to be due. However, the Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account, No. 08-3040.

Very truly yours,

HOWSON AND HOWSON Attorneys for Applicants

Cathy A) Kodroff

Registration No. 33,980

Suite 210

501 Office Center Drive Fort Washington, PA 19034

Phone: (215) 540-9200 Fax: (215) 540-5818 JUN 2 1 7006 W JUN 2 1 7006 W Under the Paperwey Reduction Act at 1995,

JUN 2 1 7000 BY PTO/SB/08B (07-05)
Approved for use through 6/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
en of Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO 10/696,256 Application Number INFORMATION DISCLOSURE October 29, 2003 Filing Date STATEMENT BY APPLICANT First Named Inventor Azrolan (Use as many sheets as necessary) Group Art Unit 1614 Raymond J. Henley III **Examiner Name** AM-100302C1USA 1 of 1 Attorney Docket Number Sheet

		OTHER PRIOR ART-NONPATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue, number(s), publisher, city and/or country where published		
	AAAA	Y. BOTTIGER, ET AL., Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus, <i>Clin. Pharmacol. Ther.</i> , January 2001, 69(1):32-40 (abstract).		
	AAAB	M. VALGIMIGLI, ET AL., Tirofiban and Sirolimus-Eluting Stent vs Abciximab and Bare-Metal Stent for Acute Myocardial Infarction, <i>JAMA</i> , May 4, 2005, Vol. 293, No. 17, pp. 2109-2117.		
	AAAC	J. MORRISETT, ET AL., Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients, <i>Journal of Lipid Research</i> , Vol. 43, 2002, pp. 1170-1180.		
	AAAD	Z. BERGER, ET AL., Rapamycin alleviates toxicity of different aggregaate-prone proteins, <i>Human Molecular Genetics</i> , 2006, Vol. 15, No. 3, pp. 433-442		
:				

Examiner Signature	Date	
-	Considered	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.